Mankind Pharma Ltd News
Mankind Pharma sets sights on Novo Nordisk's anti-obesity drug Semaglutide
The firm is focusing on specialty chronic therapies like immunotherapy, antibody-drug conjugates, and gene therapy drugs, besides peptides like Glucagon-like peptide-1 (GLP-1)
 "Mankind Pharma sets sights on Novo Nordisk's anti-obesity drug Semaglutide")
Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%
The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports
 "Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%")
Nifty Pharma index slips 3%; Natco, Glenmark, Lupin, Laurus down up to 10%
Thus far in the calendar year 2025, the Nifty Pharma index has slipped 11 per cent, as against 3.7 per cent fall in Nifty 50.
 "Nifty Pharma index slips 3%; Natco, Glenmark, Lupin, Laurus down up to 10%")
Alkem Labs, Ipca, Divi's: Three reasons why pharma stocks are falling today
Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent
 "Alkem Labs, Ipca, Divi's: Three reasons why pharma stocks are falling today")
Mankind Pharma shares crack 6% after Q3 profit drops 16%; know more
Mankind Pharma share slipped 5.61 per cent at Rs 2,487.15 a piece on the BSE in Friday's intraday trade
 "Mankind Pharma shares crack 6% after Q3 profit drops 16%; know more")
Mankind Pharma Q3FY25 results: PAT falls 16.5%, revenue rises 24%
Mankind's revenue from operations rose to Rs 3,230 crore in Q3FY25, a 24 per cent Y-o-Y rise from Rs 2,607 crore reported in Q3FY24
Q3 results today: Ultratech, HPCl, Zee among 59 to post earnings on Jan 23
Q3FY25 company results, January 23: Two Adani entities including Adani Energy Solutions and Adani Green Energy will release results for the Oct-Dec quarter today
 "Q3 results today: Ultratech, HPCl, Zee among 59 to post earnings on Jan 23")
Mankind Pharma hit with Rs 2.27 crore GST penalty, plans to challenge order
The pharmaceutical giant criticised the order as 'arbitrary and unjustified,' and confirmed plans to challenge the decision
Mankind Pharma inks pact with Innovent for immunotherapy drug in India
Mankind Pharma Ltd and Innovent Biologics on Thursday announced a partnership to exclusively license and commercialise innovative immunotherapy drug Sintilimab, used in the treatment of cancer, in the Indian market. This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region, the companies said in a joint statement. Marketed as TYVYT (sintilimab injection) in China, Sintilimab is co-developed by Innovent and Eli Lilly. "Sintilimab is not approved in India. Early next year, we will be filing for its regulatory approval in India and complete all mandatory regulatory processes, including the conducting of a phase 3 clinical trial by Mankind Pharma for its successful approval in India once we receive the permission from the regulator to conduct such clinical trials," a Mankind Pharma spokesperson said. Under the agreement with Innovent, Mankind Pharma will have exclusive rights to ..
Mankind Pharma dips 5% on profit booking after listing of QIP shares
Mankind Pharma's shares hit a record high of Rs 3,050 on Monday and rallied 13 per cent in past four trading days
 "Mankind Pharma dips 5% on profit booking after listing of QIP shares")
Nifty Pharma index rallies 2% in weak market;Ipca, Dr Reddy's gain up to 6%
At 02:37 pm; Nifty Pharma, the sole gainer among sectoral indices, was up 1.8 per cent, as compared to 1 per cent decline in the Nifty 50.
Mankind Pharma rises on launching QIP at floor price of Rs 2,616.55
The company launched its qualified institutional placement (QIP) at a floor price of Rs 2,616.55 per share aiming to raise up to Rs 3,000 crore
Mankind Pharma pledges 39.68% in Bharat Serums for Rs 5K crore NCDs
The capital raised through this pledge is expected to support Mankind Pharma's strategic initiatives and growth plans
Mankind Pharma up 6% as PAT rises 29%, margins up 220 bps in Q2FY25
Mankind Pharma declared its September quarter numbers on Tuesday after market hours
Mankind Pharma Q2 results: PAT rises 29% to Rs 659 crore, revenue up 14%
Mankind's revenue from operations rose to Rs 3,077 crore in Q2 FY25, a 13.6 per cent Y-o-Y rise from Rs 2,708 crore reported in Q2 FY24
Mankind Pharma Q2 results: Net profit rises to Rs 653 cr on higher demand
The company, which also makes Manforce condoms and Prega News pregnancy kits, said its consolidated net profit rose to RS 653 crore for the quarter ended Sep 30, a 30% climb from last year
Q2 results today: Titan, Mazagon, and Dr Reddy's among 63 to post earnings
Q2 results today, November 5: GAIL India, Oil India, Merger Paints, Mankind Pharma, and Saregama will be releasing their earnings report for the July-September quarter on Nov 5
 "Q2 results today: Titan, Mazagon, and Dr Reddy's among 63 to post earnings")
RVNL, Polycab, CG Power: Technical view on stocks that may turn large-caps
Nuvama Alternative & Quantitative Research in its early predictions on AMFI semi-annual categorization expects RVNL, Polycab India and 5 other stocks to be upgraded to large-caps.
 "RVNL, Polycab, CG Power: Technical view on stocks that may turn large-caps")
Mankind completes Rs 13,768 cr acquisition of Bharat Serums and Vaccines
The announcement was made after market hours. On Wednesday, Mankind Pharma's shares closed at Rs 2,529.80 apiece, down 1.46 per cent on the Bombay Stock Exchange (BSE)
CCI approves Mankind Pharma's purchase of Bharat Serums for $1.6 bn
Mankind Pharma, which has brands including Manforce condoms and Prega News pregnancy tests, signed an agreement to acquire Bharat Serums
